All In Biotech

Free tool

FAERS Monitor: Illuccix

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214032 or its brand name (Illuccix, Gallium Ga-68 Gozetotide). Reports on generic versions are filed under their own applications.

Reports

194

Serious

17

9% of reports

Hospitalization

5

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site pain128
  • burning sensation9
  • injection site discomfort8
  • positron emission tomogram abnormal7
  • loss of consciousness5
  • syncope5
  • chest pain4
  • drug ineffective4
  • product preparation error4
  • seizure4
  • diarrhoea3
  • injection site haemorrhage3
  • pain3
  • vomiting3
  • blood glucose decreased2

Reports by year received

View as table
YearReports
202227
202358
202453
202544
202612

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,965 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
positron emission tomogram abnormalSignal71097.8528.46,547
injection site discomfortSignal882.541.9565
injection site painSignal12845.340.95,575
product preparation errorSignal421.18.058
burning sensationSignal913.97.496
syncopeSignal55.42.314
blood glucose decreased24.51.13
loss of consciousnessSignal54.21.89
injection site haemorrhageSignal34.11.34
seizureSignal43.81.46
chest pain42.30.92
vomiting30.70.20
pain30.50.21
diarrhoea30.50.21
drug ineffective40.30.15

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.